DOCSLIB.ORG

PTPN7 Sirna Set I PTPN7 Sirna Set I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PTPN7 Sirna Set I PTPN7 Sirna Set I Catalog # Aliquot Size P34-911-05 3 x 5 nmol P34-911-20 3 x 20 nmol P34-911-50 3 x 50 nmol PTPN7 siRNA Set I siRNA duplexes targeted against three exon regions Catalog # P34-911 Lot # Z2085-26 Specificity Formulation PTPN7 siRNAs are designed to specifically knock-down The siRNAs are supplied as a lyophilized powder and human PTPN7 expression. shipped at room temperature. Product Description Reconstitution Protocol PTPN7 siRNA is a pool of three individual synthetic siRNA Briefly centrifuge the tubes (maximum RCF 4,000g) to duplexes designed to knock-down human PTPN7 mRNA collect lyophilized siRNA at the bottom of the tube. expression. Each siRNA is 19-25 bases in length. The gene Resuspend the siRNA in 50 µl of DEPC-treated water accession number is NM_002832. (supplied by researcher), which results in a 1x stock solution (10 µM). Gently pipet the solution 3-5 times to mix Gene Aliases and avoid the introduction of bubbles. Optional: aliquot LC-PTP, LPTP, HEPTP, PTPNI, BPTP-4. 1x stock solutions for storage. Storage and Stability Related Products The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the Product Name Catalog Number lyophilized and resuspended siRNAs are stored at or PTPN1 (PTP1B), Active P28-20G below -20oC. After resuspension, siRNA stock solutions ≥2 PTPN11 (SHP2), Active P38-21G µM can undergo up to 50 freeze-thaw cycles without PTPN12 (PTP-PEST), Active P39-21G significant degradation. For long-term storage, it is PTPN13 (FAP-1), Active P40-21G recommended that the siRNA is stored at -70oC. For most PTPN2 (TC-PTP), Active P29-20G favorable performance, avoid repeated handling and PTPN6 (SHP1), Active P33-20G multiple freeze/thaw cycles. PTPN7 (LC-PTP), Active P34-20G Anti-PTPN11 (SHP2) P38-63CR Scientific Background Anti-PTPN11 (SHP2) P38-63BR PTPN7 gene is preferentially expressed in a variety of hematopoietic cells, and is an early response gene in lymphokine stimulated cells (1). The noncatalytic N- terminus of this PTP can interact with MAP kinases and PTPN7 siRNA Set I siRNA duplexes targeted against three exon regions negatively regulates ERK2 and p38 MAP-kinases activity (2). The PTPN7 was shown to be involved in the regulation Catalog # P34-911 of T cell antigen receptor (TCR) signaling, which was Lot # Z2085-26 thought to function through dephosphorylating the Packaging Specifications 2.5 nmol/tube for 3 x 5 nmol molecules related to MAP kinase pathway (3). Format Lyophilized powder Stability 1yr at -70oC from date of shipment References Storage & Shipping The lyophilized powder is stable for at least 4 weeks at room temperature. It is 1. Adachi, M. et al: Protein-tyrosine phosphatase recommended that the lyophilized expression in pre-B cell NALM-6. Cancer Res. 52: 737- and resuspended siRNAs are stored at 740, 1992. or below -20oC. After resuspension, 2. Pettiford, S M. et al: The MAP-kinase ERK2 is a specific siRNA stock solutions ≥2 µM can undergo up to 50 freeze-thaw cycles substrate of the protein tyrosine phosphatase HePTP. without significant degradation. For Oncogene. 2000 Feb 17;19(7):858-69. long-term storage, it is recommended 3. Oh-hora, M. et al: Direct .suppression of TCR- that the siRNA is stored at -70oC. For most favorable performance, avoid mediated activation of extracellular signal-regulated repeated handling and multiple kinase by leukocyte protein tyrosine phosphatase, a freeze/thaw cycles. tyrosine-specific phosphatase. J Immunol. 1999 Aug 1;163(3):1282-8. To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: [email protected] www.signalchem.com FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS. .
Load more

Recommended publications
  • The Expression Patterns and the Prognostic Roles of PTPN Family Members in Digestive Tract Cancers
    Preprint: Please note that this article has not completed peer review. The expression patterns and the prognostic roles of PTPN family members in digestive tract cancers CURRENT STATUS: UNDER REVIEW Jing Chen The First Affiliated Hospital of China Medical University Xu Zhao Liaoning Vocational College of Medicine Yuan Yuan The First Affiliated Hospital of China Medical University Jing-jing Jing The First Affiliated Hospital of China Medical University [email protected] Author ORCiD: https://orcid.org/0000-0002-9807-8089 DOI: 10.21203/rs.3.rs-19689/v1 SUBJECT AREAS Cancer Biology KEYWORDS PTPN family members, digestive tract cancers, expression, prognosis, clinical features 1 Abstract Background Non-receptor protein tyrosine phosphatases (PTPNs) are a set of enzymes involved in the tyrosyl phosphorylation. The present study intended to clarify the associations between the expression patterns of PTPN family members and the prognosis of digestive tract cancers. Method Expression profiling of PTPN family genes in digestive tract cancers were analyzed through ONCOMINE and UALCAN. Gene ontology enrichment analysis was conducted using the DAVID database. The gene–gene interaction network was performed by GeneMANIA and the protein–protein interaction (PPI) network was built using STRING portal couple with Cytoscape. Data from The Cancer Genome Atlas (TCGA) were downloaded for validation and to explore the relationship of the PTPN expression with clinicopathological parameters and survival of digestive tract cancers. Results Most PTPN family members were associated with digestive tract cancers according to Oncomine, Ualcan and TCGA data. For esophageal carcinoma (ESCA), expression of PTPN1, PTPN4 and PTPN12 were upregulated; expression of PTPN20 was associated with poor prognosis.
    [Show full text]
  • Molecular Programming of Tumor-Infiltrating CD8 T Cells and IL15 Resistance
    Published OnlineFirst August 2, 2016; DOI: 10.1158/2326-6066.CIR-15-0178 Research Article Cancer Immunology Research Molecular Programming of Tumor-Infiltrating CD8þ T Cells and IL15 Resistance Andrew L. Doedens1, Mark P. Rubinstein1,2, Emilie T. Gross3, J. Adam Best1, David H. Craig2, Megan K. Baker2, David J. Cole2, Jack D. Bui3, and Ananda W. Goldrath1 Abstract Despite clinical potential and recent advances, durable immu- in the lung and spleen were activated and dramatically expanded. þ notherapeutic ablation of solid tumors is not routinely achieved. Tumor-infiltrating CD8 T cells exhibited cell-extrinsic and cell- IL15expandsnaturalkillercell(NK),naturalkillerTcell(NKT)and intrinsic resistance to IL15. Our data showed that in the case of þ CD8 T-cell numbers and engages the cytotoxic program, and thus persistent viral or tumor antigen, single-agent systemic IL15cx is under evaluation for potentiation of cancer immunotherapy. We treatment primarily expanded antigen-irrelevant or extratumoral þ found that short-term therapy with IL15 bound to soluble IL15 CD8 Tcells.Weidentified exhaustion, tissue-resident memory, þ receptor a–Fc (IL15cx; a form of IL15 with increased half-life and and tumor-specific molecules expressed in tumor-infiltrating CD8 activity) was ineffective in the treatment of autochthonous PyMT T cells, which may allow therapeutic targeting or programming þ murine mammary tumors, despite abundant CD8 T-cell infiltra- of specific subsets to evade loss of function and cytokine resist- tion. Probing of this poor responsiveness revealed that IL15cx ance, and, in turn, increase the efficacy of IL2/15 adjuvant cytokine þ only weakly activated intratumoral CD8 T cells, even though cells therapy.
    [Show full text]
  • Functional Protein Tyrosine Phosphatases in Platelets A
    FUNCTIONAL PROTEIN TYROSINE PHOSPHATASES IN PLATELETS ________________________ A Dissertation Submitted to The Temple University Graduate Board ________________________ In Partial Fulfillment Of the Requirements for the Degree DOCTOR OF PHILOSOPHY ________________________ by Vaishali Vijay Inamdar December 2017 Dissertation Examining Committee: Dr. Satya P Kunapuli, Physiology Dr. Rosario Scalia, Physiology Dr. Laurie Kilpatrick, Physiology Dr. Xiongwen Chen, Physiology Dr. Ulhas Naik, Professor, Thomas Jefferson University ABSTRACT FUNCTIONAL PHOSPHATASES IN PLATELETS Platelets are small anucleate cells in blood that are derived from megakaryocytes and their primary function is to prevent bleeding. Upon vascular injury, the sub-endothelial collagen gets exposed to which platelets bind and aggregate eventually forming a platelet plug. There are several receptors on platelet surface that can be divided into two broad categories; the immune-receptor tyrosine-based activation motif (ITAM) and the G protein-coupled receptors (GPCRs). The role of several protein tyrosine kinases (PTKs) downstream of ITAM and GPCRs has been extensively studied. However, the role of protein tyrosine phosphatases (PTPs) have been under-investigated in platelets. PTPs are important for dephosphorylating and activating or inactivating the protein. Proteomics studies show presence of 10 receptor like and 10 cytoplasmic phosphatases in platelets. To date, only five non-transmembrane PTPs (NTPTPs), PTP-1B, Shp1, Shp2, LMW-PTP, MEG2-PTP and a one receptor- like PTP (RPTP), CD148, have been identified in platelets. Therefore, there is a need to explore the role of other PTPs in platelet activation. The main objective of this thesis was to determine the role of two PTPs – CD45 and PTPN7 in platelets. We first studied the role of CD45 in platelets.
    [Show full text]
  • Live-Cell Imaging Rnai Screen Identifies PP2A–B55α and Importin-Β1 As Key Mitotic Exit Regulators in Human Cells
    LETTERS Live-cell imaging RNAi screen identifies PP2A–B55α and importin-β1 as key mitotic exit regulators in human cells Michael H. A. Schmitz1,2,3, Michael Held1,2, Veerle Janssens4, James R. A. Hutchins5, Otto Hudecz6, Elitsa Ivanova4, Jozef Goris4, Laura Trinkle-Mulcahy7, Angus I. Lamond8, Ina Poser9, Anthony A. Hyman9, Karl Mechtler5,6, Jan-Michael Peters5 and Daniel W. Gerlich1,2,10 When vertebrate cells exit mitosis various cellular structures can contribute to Cdk1 substrate dephosphorylation during vertebrate are re-organized to build functional interphase cells1. This mitotic exit, whereas Ca2+-triggered mitotic exit in cytostatic-factor- depends on Cdk1 (cyclin dependent kinase 1) inactivation arrested egg extracts depends on calcineurin12,13. Early genetic studies in and subsequent dephosphorylation of its substrates2–4. Drosophila melanogaster 14,15 and Aspergillus nidulans16 reported defects Members of the protein phosphatase 1 and 2A (PP1 and in late mitosis of PP1 and PP2A mutants. However, the assays used in PP2A) families can dephosphorylate Cdk1 substrates in these studies were not specific for mitotic exit because they scored pro- biochemical extracts during mitotic exit5,6, but how this relates metaphase arrest or anaphase chromosome bridges, which can result to postmitotic reassembly of interphase structures in intact from defects in early mitosis. cells is not known. Here, we use a live-cell imaging assay and Intracellular targeting of Ser/Thr phosphatase complexes to specific RNAi knockdown to screen a genome-wide library of protein substrates is mediated by a diverse range of regulatory and targeting phosphatases for mitotic exit functions in human cells. We subunits that associate with a small group of catalytic subunits3,4,17.
    [Show full text]
  • Phosphatases Page 1
    Phosphatases esiRNA ID Gene Name Gene Description Ensembl ID HU-05948-1 ACP1 acid phosphatase 1, soluble ENSG00000143727 HU-01870-1 ACP2 acid phosphatase 2, lysosomal ENSG00000134575 HU-05292-1 ACP5 acid phosphatase 5, tartrate resistant ENSG00000102575 HU-02655-1 ACP6 acid phosphatase 6, lysophosphatidic ENSG00000162836 HU-13465-1 ACPL2 acid phosphatase-like 2 ENSG00000155893 HU-06716-1 ACPP acid phosphatase, prostate ENSG00000014257 HU-15218-1 ACPT acid phosphatase, testicular ENSG00000142513 HU-09496-1 ACYP1 acylphosphatase 1, erythrocyte (common) type ENSG00000119640 HU-04746-1 ALPL alkaline phosphatase, liver ENSG00000162551 HU-14729-1 ALPP alkaline phosphatase, placental ENSG00000163283 HU-14729-1 ALPP alkaline phosphatase, placental ENSG00000163283 HU-14729-1 ALPPL2 alkaline phosphatase, placental-like 2 ENSG00000163286 HU-07767-1 BPGM 2,3-bisphosphoglycerate mutase ENSG00000172331 HU-06476-1 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 ENSG00000162813 HU-09086-1 CANT1 calcium activated nucleotidase 1 ENSG00000171302 HU-03115-1 CCDC155 coiled-coil domain containing 155 ENSG00000161609 HU-09022-1 CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) ENSG00000079335 HU-11533-1 CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) ENSG00000081377 HU-06323-1 CDC25A cell division cycle 25 homolog A (S. pombe) ENSG00000164045 HU-07288-1 CDC25B cell division cycle 25 homolog B (S. pombe) ENSG00000101224 HU-06033-1 CDKN3 cyclin-dependent kinase inhibitor 3 ENSG00000100526 HU-02274-1 CTDSP1 CTD (carboxy-terminal domain,
    [Show full text]
  • Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response
    DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response This information is current as Roland Lang, Michael Hammer and Jörg Mages of September 29, 2021. J Immunol 2006; 177:7497-7504; ; doi: 10.4049/jimmunol.177.11.7497 http://www.jimmunol.org/content/177/11/7497 Downloaded from References This article cites 82 articles, 53 of which you can access for free at: http://www.jimmunol.org/content/177/11/7497.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response1 Roland Lang,2 Michael Hammer, and Jo¨rg Mages The MAPK family members p38, JNK, and ERK are all promoters of e.g., Il6, Tnfa, and many other genes that are up- activated downstream of innate immunity’s TLR to in- regulated in response to TLR ligation.
    [Show full text]
  • Inhibition of Dual-Specificity Phosphatase 26 by Ethyl-3,4-Dephostatin: Ethyl-3,4-Dephostatin As a Multiphosphatase Inhibitor
    ORIGINAL ARTICLES College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor HUIYUN SEO, SAYEON CHO Received September 30, 2015, accepted November 6, 2015 Sayeon Cho, Ph.D., College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea [email protected] Pharmazie 71: 196–200 (2016) doi: 10.1691/ph.2016.5803 Protein tyrosine phosphatases (PTPs) regulate protein function by dephosphorylating phosphorylated proteins in many signaling cascades and some of them have been targets for drug development against many human diseases. There have been many reports that some chemical inhibitors could regulate particular phosphatases. However, there was no extensive study on specificity of inhibitors towardss phosphatases. We investigated the effects of ethyl-3,4-dephostatin, a potent inhibitor of five PTPs including PTP-1B and Src homology-2-containing protein tyrosine phosphatase-1 (SHP-1), on thirteen other PTPs using in vitro phosphatase assays. Of them, dual-specificity protein phosphatase 26 (DUSP26), which inhibits mitogen-activated protein kinase (MAPK) and p53 tumor suppressor and is known to be overexpressed in anaplastic thyroid carcinoma, was inhibited by ethyl- 3,4-dephostatin in a concentration-dependent manner. Kinetic studies with ethyl-3,4-dephostatin and DUSP26 revealed competitive inhibition, suggesting that ethyl-3,4-dephostatin binds to the catalytic site of DUSP26 like other substrate PTPs. Moreover, ethyl-3,4-dephostatin protects DUSP26-mediated dephosphorylation of p38, a member of the MAPK family, and p53. Taken together, these results suggest that ethyl-3,4-dephostatin functions as a multiphosphatase inhibitor and is useful as a therapeutic agent for cancers overexpressing DUSP26.
    [Show full text]
  • Protein Tyrosine Phosphatases in Health and Disease Wiljan J
    REVIEW ARTICLE Protein tyrosine phosphatases in health and disease Wiljan J. A. J. Hendriks1, Ari Elson2, Sheila Harroch3, Rafael Pulido4, Andrew Stoker5 and Jeroen den Hertog6,7 1 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 2 Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel 3 Department of Neuroscience, Institut Pasteur, Paris, France 4 Centro de Investigacio´ nPrı´ncipe Felipe, Valencia, Spain 5 Neural Development Unit, Institute of Child Health, University College London, UK 6 Hubrecht Institute, KNAW & University Medical Center Utrecht, The Netherlands 7 Institute of Biology Leiden, Leiden University, The Netherlands Keywords Protein tyrosine phosphatases (PTPs) represent a super-family of enzymes bone morphogenesis; hereditary disease; that play essential roles in normal development and physiology. In this neuronal development; post-translational review, we will discuss the PTPs that have a causative role in hereditary modification; protein tyrosine phosphatase; diseases in humans. In addition, recent progress in the development and synaptogenesis analysis of animal models expressing mutant PTPs will be presented. The Correspondence impact of PTP signaling on health and disease will be exemplified for the J. den Hertog, Hubrecht Institute, fields of bone development, synaptogenesis and central nervous system dis- Uppsalalaan 8, 3584 CT Utrecht, eases. Collectively, research on PTPs since the late 1980’s yielded the The Netherlands cogent view that development of PTP-directed
    [Show full text]
  • Complex Oncogene Dependence in Microrna-125A– Induced Myeloproliferative Neoplasms
    Complex oncogene dependence in microRNA-125a– induced myeloproliferative neoplasms Shangqin Guoa,b, Haitao Baib,c, Cynthia M. Megyolaa,b, Stephanie Halenea,d,e, Diane S. Krausea,e,f, David T. Scaddeng, and Jun Lua,b,e,1 bDepartment of Genetics, dDepartment of Medicine, fDepartment of Laboratory Medicine, aYale Stem Cell Center, and eYale Cancer Center, Yale University School of Medicine, New Haven, CT 06520; gCenter for Regenerative Medicine, Massachusetts General Hospital, Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Boston, MA 02114; and cDepartment of Hematology, Shanghai First People’s Hospital Shanghai 200080, China Edited by Sherman M. Weissman, Yale University, New Haven, CT, and approved August 30, 2012 (received for review August 2, 2012) Deregulation of microRNA (miRNA) expression can lead to cancer neoplasms, MPNs) are a collection of hematopoietic diseases initiation and progression. However, limited information exists on the with common features (reviewed in refs. 13 and 14), such as function of miRNAs in cancer maintenance. We examined these issues overproduction of one or more myeloid/erythroid/platelet line- in the case of myeloproliferative diseases and neoplasms (MPN), ages and splenomegaly. In some patients, the MPN will progress a collection of hematopoietic neoplasms regarded as preleukemic, to acute myeloid leukemia, leading to the notion that MPN is thereby representing early neoplastic states. We report here that one of the preleukemic states of a full-blown myeloid leukemia. microRNA-125a (miR-125a)–induced MPN display a complex manner In this study, we used genomics and genetics to explore the role of oncogene dependence. Following a gain-of-function genomics of miRNAs in MPN and the dependence of the early neoplastic screen, we overexpressed candidate miR-125a in vivo, which led MPN state on an oncogenic miRNA.
    [Show full text]
  • Mutations in the RAS-BRAF-MAPK-ERK Pathway
    Chronic Lymphocytic Leukemia SUPPLEMENTARY APPENDIX Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia Neus Giménez, 1,2 * Alejandra Martínez-Trillos, 1,3 * Arnau Montraveta, 1 Mónica Lopez-Guerra, 1,4 Laia Rosich, 1 Ferran Nadeu, 1 Juan G. Valero, 1 Marta Aymerich, 1,4 Laura Magnano, 1,4 Maria Rozman, 1,4 Estella Matutes, 4 Julio Delgado, 1,3 Tycho Baumann, 1,3 Eva Gine, 1,3 Marcos González, 5 Miguel Alcoceba, 5 M. José Terol, 6 Blanca Navarro, 6 Enrique Colado, 7 Angel R. Payer, 7 Xose S. Puente, 8 Carlos López-Otín, 8 Armando Lopez-Guillermo, 1,3 Elias Campo, 1,4 Dolors Colomer 1,4 ** and Neus Villamor 1,4 ** 1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona; 2Anaxomics Biotech, Barcelona; 3Hematol - ogy Department and 4Hematopathology Unit, Hospital Clinic, Barcelona; 5Hematology Department, University Hospital- IBSAL, and In - stitute of Molecular and Cellular Biology of Cancer, University of Salamanca, CIBERONC; 6Hematology Department, Hospital Clínico Universitario, Valencia: 7Hematology Department, Hospital Universitario Central de Asturias, Oviedo, and 8Departamento de Bio - química y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, CIBERONC, Spain. *NG and AM-T contributed equally to the study. **DC and NV share senior authorship of the manuscript. ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.196931 Received: May 1, 2018. Accepted: September 26, 2018. Pre-published: September 27, 2018. Correspondence: DOLORS COLOMER [email protected] Supplemental data METHODS Primary CLL cells Cells were isolated from peripheral blood (PB) samples by Ficoll-Paque sedimentation (GE-Healthcare, Chicago, IL, USA).
    [Show full text]
  • Identification of PTPN1 As a Novel Negative Regulator of the JNK MAPK
    www.nature.com/scientificreports OPEN Identifcation of PTPN1 as a novel negative regulator of the JNK MAPK pathway using a synthetic Received: 22 May 2017 Accepted: 25 September 2017 screening for pathway-specifc Published: xx xx xxxx phosphatases Jiyoung Moon , Jain Ha & Sang-Hyun Park The mitogen activated protein kinase (MAPK) signaling cascades transmit extracellular stimulations to generate various cellular responses via the sequential and reversible phosphorylation of kinases. Since the strength and duration of kinase phosphorylation within the pathway determine the cellular response, both kinases and phosphatases play an essential role in the precise control of MAPK pathway activation and attenuation. Thus, the identifcation of pathway-specifc phosphatases is critical for understanding the functional mechanisms by which the MAPK pathway is regulated. To identify phosphatases specifc to the c-Jun N-terminal kinase (JNK) MAPK pathway, a synthetic screening approach was utilized in which phosphatases were individually tethered to the JNK pathway specifc-JIP1 scafold protein. Of 77 mammalian phosphatases tested, PTPN1 led to the inhibition of JNK pathway activation. Further analyses revealed that of three pathway member kinases, PTPN1 directly dephosphorylates JNK, the terminal kinase of the pathway, and negatively regulates the JNK MAPK pathway. Specifcally, PTPN1 appears to regulate the overall signaling magnitude, rather than the adaptation timing, suggesting that PTPN1 might be involved in the control and maintenance of signaling noise. Finally, the negative regulation of the JNK MAPK pathway by PTPN1 was found to reduce the tumor necrosis factor α (TNFα)-dependent cell death response. Te mitogen-activated protein kinase (MAPK) pathways are evolutionally conserved among eukaryotes, and regulate diverse cellular responses, including cell proliferation, differentiation, and death1,2.
    [Show full text]
  • Research Article Gene Expression Profiles of Human Phosphotyrosine Phosphatases Consequent to Th1 Polarisation and Effector Function
    Hindawi Journal of Immunology Research Volume 2017, Article ID 8701042, 12 pages https://doi.org/10.1155/2017/8701042 Research Article Gene Expression Profiles of Human Phosphotyrosine Phosphatases Consequent to Th1 Polarisation and Effector Function Patricia Castro-Sánchez, Rocio Ramirez-Munoz, and Pedro Roda-Navarro Department of Microbiology I (Immunology), School of Medicine, Complutense University and “12 de Octubre” Health Research Institute, Madrid, Spain Correspondence should be addressed to Pedro Roda-Navarro; [email protected] Received 4 December 2016; Accepted 14 February 2017; Published 14 March 2017 Academic Editor: Andreia´ M. Cardoso Copyright © 2017 Patricia Castro-Sanchez´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Phosphotyrosine phosphatases (PTPs) constitute a complex family of enzymes that control the balance of intracellular phosphorylation levels to allow cell responses while avoiding the development of diseases. Despite the relevance of CD4 T cell polarisation and effector function in human autoimmune diseases, the expression profile of PTPs during T helper polarisation and restimulation at inflammatory sites has not been assessed. Here, a systematic analysis of the expression profile of PTPs hasbeen 2+ carried out during Th1-polarising conditions and upon PKC activation and intracellular raise of Ca in effector cells. Changes in gene expression levels suggest a previously nonnoted regulatory role of several PTPs in Th1 polarisation and effector function. A substantial change in the spatial compartmentalisation of ERK during T cell responses is proposed based on changes in the dose of cytoplasmic and nuclear MAPK phosphatases.
    [Show full text]